본문 바로가기
KERD
논문KCI 등재

Current progress on development of respiratory syncytial virus vaccine

장준
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2011.04|BMB Reports|제44권 제4호|pp. 232-237

2

조회

0

다운로드

6

인용

0

참고문헌

키워드

ProtectionVaccinePathogenesisRespiratory syncytial virusVaccine strategy
주제분류화학

초록

Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection,2) immature immune system and maternal antibodies of newborn infants who are the primary subject population,and 3) imbalanced Th2-biased immune responses to certain vaccine candidates leading to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. A wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vectorbased candidates. Though licensed vaccines remain to be developed,our great efforts will lead us to reach the goal of attaining safe and effective RSV vaccines in the near future. [BMB reports 2011; 44(4): 232-237]

Abstract

Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection,2) immature immune system and maternal antibodies of newborn infants who are the primary subject population,and 3) imbalanced Th2-biased immune responses to certain vaccine candidates leading to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. A wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vectorbased candidates. Though licensed vaccines remain to be developed,our great efforts will lead us to reach the goal of attaining safe and effective RSV vaccines in the near future. [BMB reports 2011; 44(4): 232-237]

참고문헌 (58)

  1. Hall, C. B, "Immunity to and frequency of reinfection with respiratory syncytial virus", J. Infect Dis, 163, pp.693~698 (1991)
  2. Walsh, E. E, "Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection", J. Infect Dis, 155, pp.1198~1204 (1987)
  3. Connors, M, "Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived", J. Virol, 65, pp.1634~1637 (1991)
  4. Johnson, P. R, "The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins", Proc. Natl. Acad. Sci. U.S.A, 84, pp.5625~5629 (1987)
  5. Johnson, S, "Development of a humanized monoclonal antibody (MEDI- 493) with potent in vitro and in vivo activity against respiratory syncytial virus", J. Infect Dis, 176, pp.1215~1224 (1997)
  6. Graham, B. S, "Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice", J. Clin. Invest, 88, pp.1026~1033 (1991)
  7. Alwan, W. H, "CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells", Clin. Exp. Immunol, 88, pp.527~536 (1992)
  8. Kapikian, A. Z, "An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine", Am. J. Epidemiol, 89, pp.405~421 (1969)
  9. Murphy, B. R, "Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion- inhibiting activity", J. Clin. Microbiol, 26, pp.1595~1597 (1988)
  10. Waris, M. E, "Respiratory synctial virus infection in BALB", c mice previously immunized with formalininactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern, 1996, pp.70, 2852~2860
  11. De Swart, R. L, "Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13- associated hypersensitivity to subsequent RSV infection", J. Virol, 76, pp.11561~11569 (2002)
  12. Connors, M, "Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB", c mice is abrogated by depletion of interleukin- 4 (IL-4) and IL-10, 1994, pp.68, 5321~5325
  13. Levine, S, "Demonstration that glycoprotein G is the attachment protein of respiratory syncytial", J. Gen. Virol, 68(Pt 9), pp.2524~ (1987)
  14. Taylor, G, "Monoclonal antibodies protect against respiratory syncytial virus infection in mice", Immunology, 52, pp.137~142 (1994)
  15. Sparer, T. E, "Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia", J. Exp. Med, 187, pp.1921~1926 (1998)
  16. Martinez, I, "Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein", J. Gen. Virol, 79(Pt 9), pp.2215~2220 (1998)
  17. Bastien, N, "Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines", Vaccine, 17, pp.832~836 (1999)
  18. Srikiatkhachorn, A, "Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection", J. Exp. Med, 186, pp.421~432 (1997)
  19. Martinez, I, "Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants", J. Gen. Virol, 78(Pt 10), pp.2419~2429 (1997)
  20. Connors, M, "Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies", J. Virol, 66, pp.1277~1281 (1992)
  21. Nicholas, J. A, "Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins", J. Virol, 64, pp.4232~4241 (1990)
  22. Heidema, J, "Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes", J. Gen. Virol, 85, pp.2365~2374 (2004)
  23. Johnson, T. R, "Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge", J. Virol, 72, pp.2871~2880 (1998)
  24. Openshaw, P. J, "Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G", Int. Immunol, 4, pp.493~500 (1992)
  25. Hancock, G. E, "Generation of atypical pulmonary inflammatory responses in BALB", c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus, 1996, pp.70, 7783~7791
  26. Tebbey, P. W, "Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus", J. Exp. Med, 188, pp.1967~1972 (1998)
  27. Johnson, T. R, "Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin- inactivated RSV", J. Virol, 78, pp.8753~8760 (2004)
  28. Johnson, T. R, "Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV", J. Virol, 78, pp.6024~6032 (2004)
  29. Crowe, J. E, "Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines", J. Immunol, 167, pp.3910~3918 (2001)
  30. Glezen, W. P, "Risk of primary infection and reinfection with respiratory syncytial virus", Am. J. Dis. Child, 140, pp.543~546 (1986)
  31. Henderson, F. W, "Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children", N. Engl. J. Med, 300, pp.530~534 (1979)
  32. Bukreyev, A, "The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor- bearing leukocytes", J. Virol, 92, pp.12191~12204 (2008)
  33. Chang, J, "Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract", Nat. Med, 8, pp.54~60 (2002)
  34. Schlender, J, "Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact", J. Virol, 76, pp.1163~1170 (2002)
  35. Pringle, C. R, "Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers", Vaccine, 11, pp.473~478 (1993)
  36. Wright, P. F, "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy", J. Infect. Dis, 182, pp.1331~1342 (2000)
  37. Karron, R. A, "Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants", J. Infect. Dis, 191, pp.1093~1104 (2005)
  38. Wright, P. F, "The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans", J. Infect Dis, 193, pp.573~581 (2006)
  39. Murphy, B. R, "Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin- inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization", Vaccine, 8, pp.497~502 (1990)
  40. Murphy, B. R, "Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease", Vaccine, 7, pp.533~540 (1989)
  41. Prince, G. A, "Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease", Vaccine, 19, pp.2048~2054 (2001)
  42. Hancock, G. E, "Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus", Vaccine, 21, pp.4348~4358 (2003)
  43. Piedra, P. A, "Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis", Vaccine, 21, pp.2448~2460 (2003)
  44. Tristram, D. A, "Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old", J. Infect. Dis, 167, pp.191~195 (1993)
  45. Groothuis, J. R, "Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia", J. Infect. Dis, 177, pp.467~469 (1998)
  46. de Waal, L, "Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge", Vaccine, 22, pp.915~922 (2004)
  47. Power, U. F, "Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults", J. Infect Dis, 184, pp.1456~1460 (2001)
  48. Kohlmann, R, "Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus", J. Virol, 83, pp.12601~12610 (2009)
  49. Yu, J. R, "Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection", JOURNAL OF VIROLOGY, 82, pp.2350~2357 (2008), AMER SOC MICROBIOLOGY
  50. Hsu, K. H, "Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee", J. Infect Dis, 166, pp.769~775 (1992)
  51. Takimoto, T, "Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus", Viral. Immunol, 18, pp.255~266 (2005)
  52. Schmidt, A. C, "Recombinant bovine", human parainfluenza virus type 3 (B, J. Virol, pp.2001, 75[DOI]
  53. Elliott, M. B, "Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB", c mice and functional serum antibodies in rhesus macaques, 2007, pp.25, 7132~7144
  54. Mok, H, "Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats", J. Virol, 81, pp.13710~13722 (2007)
  55. Cano, F, "Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides", Vaccine, 18, pp.2743~2752 (2000)
  56. Martinez-Sobrido, L, "Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector", J. Virol, 80, pp.1130~1139 (2006)
  57. Bembridge, G. P, "Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein", Vaccine, 19, pp.1038~1046 (2000)
  58. Li, X, "Protection against respiratory syncytial virus infection by DNA immunization", J. Exp. Med, 188, pp.681~688 (1998)

관련 논문AI추천

Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease장준, Sol Kim대한면역학회 · Immune Network2012 · 제12권 제1호Virus-like Particle Vaccines Containing RSV Fusion Protein Cleavage Mutations Are Immunogenic and Protective in Cotton Rats With a Prime Dose강상무, 황혜숙, Kim Ki-Hye, Ko Eun-Ju, Kwon Young-Man, Lee Young-Tae, Meas Arun대한면역학회 · Immune Network2025 · 제25권 제5호Recent Advances in the Prevention of RSV in Neonates and Young InfantsYun Ki Wook대한소아감염학회 · Pediatric Infection and Vaccine2023 · 제30권 제1호Immunogenicity and Protective Efficacy of a Dual Subunit Vaccine Against Respiratory Syncytial Virus and Influenza Virus장준, 박민희대한면역학회 · Immune Network2012 · 제12권 제6호Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform강상무, 권영만, 김기혜, 김민철, 이영태, 이유나, 이유리, 황혜숙, Fu Shi Quan, Martin L. Moore대한면역학회 · Immune Network2019 · 제19권 제3호Innate immune recognition of respiratory syncytial virus infection김태훈, 이흥규생화학분자생물학회 · BMB Reports2014 · 제47권 제4호

이 간행물의 다른 논문 (10건)

Mechanism of T cell exhaustion in a chronic environment정윤희, 박효진, Hyun-Tak Jin, 하상준pp. 217-231Functional analysis of expressed sequence tags from the liver and brain of Korean Jindo dogsJong Seok Kim, Seok Il Oh, Jae Young Kim, Hye Sun Park, Dajeong Lim, Hong Chul Jang, Hae Suk Park, Kyung Tai Lee, Mu Sik Kweon, Tae Hun Kim, Bong Hwan Choipp. 238-243Ex12 helper phage improves the quality of a phage-displayed antibody library by ameliorating the adverse effect of clonal variationsSang-hoon Cha, Suk-yoon Song, Li-kun Liu, Jae-bong Yoon, Hyo-jung Choi, Jae Youl Chopp. 244-249Predicting tissue-specific expressions based on sequence characteristicsSeung-Won Seo, 허철구, 이도헌, Hyojung Paik, Taewoo Ryu, Hyoung-Sam Heopp. 250-255The protein truncation caused by fusion of PEP-1 peptide and protective roles of transduced PEP-1-MsrA in skin cells김화영, Tae-Hyung Lee, Seung Hee Choipp. 256-261
원문 보기